“janet-woodcock” Archives

in
Entry Author Date Location
FDA Panel Pans PTC’s Audacious Plan to Force Vote on Duchenne Drug 09/28/17 New York
Bio Roundup: RNAi’s Big Day, CAR-T For Kids, Drugs From Fungi & More 09/22/17 National
Immunotherapy Safety Worries Halt Celgene Myeloma Study, Slow 5 Others 09/07/17 New York
Woodcock: New Approvals Show FDA Is Adapting to Precision Medicine 05/30/17 National
After Sarepta’s Surprising FDA Nod, CEO Kaye Plans to Resign 04/28/17 Boston
Often Advocates Of Faster FDA, Patient Groups Wary Of Trump Deregulation 02/10/17 National
Ex-FDA Commish Califf Gives Props to Patient Groups—With Caveats 01/23/17 National
Notes From The JPM ’17 Vortex: Trump, Rainstorms & The Price You Pay 01/13/17 National
Senate Approves 21st Century Cures Act, Sending Bill to Obama 12/07/16 National
Defying Patient Pressure, Anthem Says No to Sarepta’s Duchenne Drug 10/07/16 Boston
Bio Execs Talk Patient Advocacy, Duchenne Approval at BioForward Panel 09/28/16 Wisconsin
Bio Roundup: Mylan Grilled, Duchenne Kids Thrilled, Zuck-Chan & More 09/23/16 National
Sarepta Preps For Sales As Insurers Unlikely To Deny Duchenne Drug 09/22/16 Boston
Sarepta Prices $300K Duchenne Drug As FDA Rift Emerges Over Approval 09/19/16 Boston
After New Data, FDA Bucks Advisory Panel, Approves Sarepta’s Duchenne Drug 09/19/16 Boston
Duchenne Lessons: Advocates For Rare Spinal Disease Have Eyes on FDA 08/26/16 National
Sarepta Saga Drags On as FDA Delays Decision on Duchenne Drug 05/25/16 Boston
Near-Term FDA Nod Unlikely For Duchenne Drug After Negative Vote 04/25/16 Boston
If You’ve Got a Real Breakthrough, the FDA Wants To Talk 01/14/13 National
Vivus Wins FDA Approval for Obesity Drug, After Long, Messy Day 07/17/12 San Francisco
The Cancer Drug Dark Ages Are Coming to an End 10/31/11 National
Alkermes Sees Chance to Reinvent Vivitrol For Fighting Drug Addiction, Not Just Alcoholism 02/18/11 Boston
Momenta Pharma Competitor Lodges Ethics Complaint Against FDA Boss, WSJ Reports 08/12/09 Boston
Page 1 of 1